Furthermore, we observed higher iron levels in CD138+ samples obtained from bone marrow aspiration of non-response patients and a more aggressive Vk*MYC Vk12653 MM model, suggesting that relapsed and refractory MM patients may be the better candidates for ferroptosis-based-therapy in the clinic. The gene discussed is SDC1; the disease is Miyoshi myopathy.